Type Whole antibody Target CGRPR Legal status Investigational | Source Human ATC code none CAS Number 1582205-90-0 | |
Erenumab (INN; developmental code name AMG-334) is a human monoclonal antibody against the calcitonin gene-related peptide receptor (CGRPR) designed for the prevention of migraine.
This drug was developed by Amgen Inc.
Clinical trials
In a Phase III clinical trial with 577 patients, the drug significantly reduced the number of migraine days per month by 3, versus 1.8 under placebo.
References
Erenumab Wikipedia(Text) CC BY-SA